Abstract:BACKGROUND:Intravenous (IV) recombinant plasminogen activator (rt-PA) within 4.5 hours of symptom onset has established benefit for patients with acute ischemic stroke (AIS); however, evidence on the use of IV rt-PA in elderly Chinese patients is limited. This study evaluated the patient characteristics and in-hospital clinical outcomes of Chinese patients aged >80 years who received IV rt-PA within 4.5 h of symptom onset, using patients aged 18-80 years as a reference group. (NCT05395351). METHODS:This study analyzed adult Chinese patients with AIS who arrived at the hospital within 4.5 hours of symptom onset between August 2015 and July 2019 and were registered in the nationwide, hospital-based Chinese Stroke Center Alliance platform. Patients were categorized by treatment (IV rt-PA versus no IV rt-PA) and age (>80 years versus 18-80 years). In-hospital outcomes were evaluated in IV rt-PA-treated patients. Primary outcome was all-cause mortality during hospitalization; secondary outcomes included proportion of patients with intracranial hemorrhage (ICH) during hospitalization, change in National Institutes of Health Stroke Scale (NIHSS) before and 24 h after IV rt-PA, modified Rankin Scale (mRS) at discharge, proportion of patients with stroke recurrence during hospitalization, and duration of hospital stay. RESULTS:Of 113,035 patients with AIS included in the study, 31,418 patients received IV rt-PA within 4.5 hours after symptom onset (aged >80 years: n=3,332; 18-80 years: n=28,086). Among IV rt-PA-treated patients, all-cause mortality was 2.6 % (95 % CI 2.1-3.2 %) and 0.8 % (95 % CI 0.7-0.9 %) in patients aged >80 years and 18-80 years, respectively. Intracranial hemorrhage occurred in 6.7 % (95 % CI 5.8-7.5 %) and 3.1 % (95 % CI 2.9-3.3 %) of patients; mean±SD change in NIHSS score was 2.8±5.0 and 2.5±4.3; mRS 0-1 at discharge in 42.8 % (95 % CI 40.8 %-44.8 %) and 63.6 % (95 % CI 62.9 %-64.3 %); stroke recurrence in 11.1 % (95 % CI 10.0-12.1 %) and 7.3 % (95 % CI 7.0-7.6 %). Median duration of hospital stay was 11 days in both age groups. CONCLUSIONS:Chinese patients aged >80 years with AIS who received IV rt-PA within 4.5 hours after symptom onset had higher all-cause mortality during hospitalization than those aged 18-80 years.

Use of Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients: Evaluation of Clinical Outcomes

Study of intravenous thrombolysis with recombinant tissue plasminogen activator(rtPA)in isolatedpenetrating artery territory infarcts

[Factors Related to Therapeutic Outcomes of Intravenous Thrombolysis in Stroke Patients with Different Severity].

Minor Non-Disabling Stroke Patients with Large Vessel Severe Stenosis or Occlusion Might Benefit from Thrombolysis

Stroke Outcome of Early Antiplatelet in Post-Thrombolysis Haemorrhagic Infarction.

Non-atrial Fibrillation Was Associated with Early Neurological Improvement after Intravenous Thrombolysis with Rt-Pa in Patients with Acute Ischemic Stroke

Improving In-Hospital Stroke Service Utilization (MISSION) to Shorten Thrombolytic Door-to-needle Time in Acute Ischemic Stroke Patients: A Cluster Randomized Controlled Trial

Effect of Intravenous Thrombolysis of Alteplase in Treatment of Acute Ischemic Stroke

Early Tirofiban Administration for Patients with Acute Ischemic Stroke Treated with Intravenous Thrombolysis or Bridging Therapy: Systematic Review and Meta-Analysis

Clinical analysis of thrombolytic therapy with ischemic in-hospital stroke

Intravenous Thrombolysis Treatment Compliance with Alteplase in Patients with Acute Ischemic Stroke in Huashan Hospital

Tenecteplase Thrombolytic Therapy for Acute Ischaemic Stroke in China: a Real-World, Multicentre, Retrospective, Controlled Study

Effectiveness and prognosis-related factors of intravenous thrombolysis in patients with acute ischemic stroke

Rates of Intravenous Thrombolysis and Endovascular Therapy for Acute Ischaemic Stroke in China Between 2019 and 2020.

Efficacy and Safety of Tirofiban in Clinical Patients with Acute Ischemic Stroke

Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis

Abstract TP75: Safety and Outcome of Thrombolysis in Acute Stroke with Prolonged Onset-to-Treatment Times and Low National Institute of Health Stroke Scale Scores. Report on Experience in China, First 1000 Patients of 3300 Treated

Young Stroke Patients Treated with Intravenous Thrombolysis have a More Favorable Outcome and Mortality Compared with Older Patients.

In-hospital Outcomes of Intravenous Recombinant Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke in Patients Aged >80 Years: Findings from the Chinese Stroke Center Alliance

Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study

Intravenous Thrombolytic Therapy for Acute Ischemic Stroke in Hubei, China: a Survey of Thrombolysis Rate and Barriers.